Skip to main content

Table 1 Demographic data of the 54 statin users in the study cohort. Age, lab values, and survival time is at time of inclusion in the original studies [16, 19]. All values are presented as mean ± SD if not specified otherwise. P values show statistically significant differences between women and men. Survival time is from time of inclusion in the original vitamin D study

From: Differences in discontinuation of statin treatment in women and men with advanced cancer disease

 

Total (N = 54)

Men (N = 25)

Women (N = 29)

p

Patients’ characteristics

Age (years)

72 ± 10

71 ± 11

73 ± 8

ns

Age > 75 years, n (%)

20

10

10

ns

Albumin (g/L)

27 ± 7

27 ± 6

27 ± 7

ns

CRP (mg/L)

65 ± 27

63 ± 126

66 ± 82

ns

25-OHD (nmol/L)

45 ± 29

43 ± 26

47 ± 32

ns

ESAS QoL

5.7 ± 2.5

6.5 ± 2.4

5.0 ± 2.4

0.03

History of stroke, n

6

4

2

ns

History of myocardial infarction, n

12

8

4

ns

Survival time (months)

3.3 ± 4.5

2.2 ± 2.5

4.3 ± 5.5

ns

(0.10)

Highest educational level

 University degree

4

2

2

ns

 No university degree

30

14

16

ns

 Unknown

20

9

11

ns

Indication for statin use

 Primary prevention, n

36

13

23

 

 Secondary prevention, n

18

12

6

0.03

Type of statin, n

mean dose (mg)

 Simvastatin

41

28 mg

21

31 mg

20

24 mg

ns

 Atorvastatin

10

23 mg

3

27 mg

7

19 mg

ns

 Rosuvastatin

2

10 mg

0

2

10 mg

ns

 Pravastatin

1

20 mg

1

20 mg

0

ns

  1. ESAS QoL: The Edmonton Symptom Assessment System, Quality of life assessment, a scale from 0 to 10
  2. CRP: C reactive protein, 25-OHD: 25-hydroxyvitamin D, ns: non-significant